Cethrin: Phase I/IIa expanded

ALSE expanded an open-label, dose-escalation, U.S. and Canadian Phase I/IIa trial to evaluate 9 mg of Cethrin in patients with cervical SCI. The protocol modification is based on safety analyses of da...